Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe

Abstract The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in patients with DLBCL with rituximab biosimilars are limited....

Full description

Bibliographic Details
Main Authors: Mark J. Bishton, Gilles Salles, Camille Golfier, Wolfgang Knauf, Monica Bocchia, Deborah Turner, Borhane Slama, Jatinder Harchowal, Scott Marshall, Alberto Bosi, Juan José Bargay Lleonart, Manfred Welslau, SooKyoung Kim, Young N. Lee, Pier L. Zinzani, Kamel Laribi
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:eJHaem
Subjects:
biosimilar
DLBCL
NHL
rituximab
Online Access:https://doi.org/10.1002/jha2.593

Internet

https://doi.org/10.1002/jha2.593

Similar Items